BMO Capital Markets reaffirmed their outperform rating on shares of Incyte Corp. (NASDAQ:INCY) in a research report report published on Saturday. BMO Capital Markets currently has a $126.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $121.00.

Other equities analysts also recently issued reports about the stock. SunTrust Banks Inc. initiated coverage on shares of Incyte Corp. in a report on Friday, August 5th. They issued a buy rating and a $105.00 price objective on the stock. Piper Jaffray Cos. reiterated a buy rating and issued a $102.00 price objective (up from $76.00) on shares of Incyte Corp. in a report on Monday, August 1st. Jefferies Group reiterated a buy rating and issued a $98.00 price objective on shares of Incyte Corp. in a report on Wednesday, August 10th. JPMorgan Chase & Co. reiterated a buy rating on shares of Incyte Corp. in a report on Wednesday, September 28th. Finally, Argus upped their price objective on shares of Incyte Corp. from $92.00 to $98.00 and gave the company a buy rating in a report on Monday, September 26th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and twenty-one have given a buy rating to the company’s stock. Incyte Corp. has a consensus rating of Buy and an average target price of $103.73.

Analyst Recommendations for Incyte Corp. (NASDAQ:INCY)

Shares of Incyte Corp. (NASDAQ:INCY) traded down 1.82% during midday trading on Friday, hitting $103.63. 1,103,094 shares of the company were exchanged. Incyte Corp. has a one year low of $55.00 and a one year high of $118.49. The company has a market capitalization of $19.52 billion, a P/E ratio of 139.29 and a beta of 0.79. The company has a 50-day moving average of $92.87 and a 200 day moving average of $84.56.

In other news, EVP Paula J. Swain sold 10,000 shares of the firm’s stock in a transaction on Thursday, October 20th. The stock was sold at an average price of $90.00, for a total transaction of $900,000.00. Following the completion of the sale, the executive vice president now directly owns 39,248 shares of the company’s stock, valued at approximately $3,532,320. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Barry P. Flannelly sold 24,204 shares of the firm’s stock in a transaction on Friday, October 7th. The shares were sold at an average price of $97.00, for a total value of $2,347,788.00. Following the sale, the executive vice president now directly owns 13,595 shares of the company’s stock, valued at $1,318,715. The disclosure for this sale can be found here. Company insiders own 13.70% of the company’s stock.

Large investors have recently made changes to their positions in the stock. Fuller & Thaler Asset Management Inc. acquired a new stake in shares of Incyte Corp. during the second quarter valued at about $104,000. Acrospire Investment Management LLC raised its stake in shares of Incyte Corp. by 18.2% in the second quarter. Acrospire Investment Management LLC now owns 1,300 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 200 shares in the last quarter. Seven Eight Capital LLC acquired a new stake in shares of Incyte Corp. during the first quarter valued at about $113,000. Walleye Trading LLC acquired a new stake in shares of Incyte Corp. during the second quarter valued at about $120,000. Finally, Fifth Third Bancorp raised its stake in shares of Incyte Corp. by 16.2% in the second quarter. Fifth Third Bancorp now owns 1,678 shares of the biopharmaceutical company’s stock valued at $134,000 after buying an additional 234 shares in the last quarter. 92.14% of the stock is owned by hedge funds and other institutional investors.

Incyte Corp. Company Profile

Incyte Corporation is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat medical needs, primarily in oncology. The Company focuses on the research and development program to explore the inhibition of enzymes called janus associated kinases (JAK).

5 Day Chart for NASDAQ:INCY

Receive News & Stock Ratings for Incyte Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corp. and related stocks with our FREE daily email newsletter.